A detailed history of Rhenman & Partners Asset Management Ab transactions in Natera, Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 231,000 shares of NTRA stock, worth $39.2 Million. This represents 2.45% of its overall portfolio holdings.

Number of Shares
231,000
Previous 157,000 47.13%
Holding current value
$39.2 Million
Previous $17 Million 72.7%
% of portfolio
2.45%
Previous 1.68%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$97.75 - $129.67 $7.23 Million - $9.6 Million
74,000 Added 47.13%
231,000 $29.4 Million
Q2 2024

Aug 13, 2024

SELL
$85.28 - $112.6 $7.08 Million - $9.35 Million
-83,000 Reduced 34.58%
157,000 $17 Million
Q1 2024

May 14, 2024

SELL
$59.21 - $92.9 $296,050 - $464,500
-5,000 Reduced 2.04%
240,000 $22 Million
Q4 2023

Feb 13, 2024

SELL
$37.55 - $62.64 $817,425 - $1.36 Million
-21,769 Reduced 8.16%
245,000 $15.3 Million
Q3 2023

Nov 13, 2023

BUY
$43.4 - $62.52 $2.9 Million - $4.17 Million
66,769 Added 33.38%
266,769 $11.8 Million
Q2 2023

Aug 11, 2023

SELL
$47.08 - $55.16 $800,360 - $937,720
-17,000 Reduced 7.83%
200,000 $9.73 Million
Q1 2023

May 11, 2023

BUY
$36.57 - $58.29 $1.9 Million - $3.03 Million
52,000 Added 31.52%
217,000 $12 Million
Q4 2022

Feb 13, 2023

BUY
$34.17 - $47.91 $2.9 Million - $4.07 Million
85,000 Added 106.25%
165,000 $6.63 Million
Q3 2022

Nov 14, 2022

BUY
$36.93 - $56.68 $2.95 Million - $4.53 Million
80,000 New
80,000 $3.76 Million

Others Institutions Holding NTRA

About Natera, Inc.


  • Ticker NTRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 96,957,400
  • Market Cap $16.5B
  • Description
  • Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify sing...
More about NTRA
Track This Portfolio

Track Rhenman & Partners Asset Management Ab Portfolio

Follow Rhenman & Partners Asset Management Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.